IBD advanced therapies
Biologics, JAK inhibitors and S1P modulators for moderate–severe Crohn’s disease and UC. Pick by phenotype, comorbidity and route, not by a fixed ladder. Screen for HBV, TB and VZV before the first dose; give live vaccines ≥4 weeks before or not at all — but never delay urgent therapy to vaccinate. First advanced therapy has the best response rate.
classes
| class | agents | route | CD | UC | best for | avoid / caution |
|---|---|---|---|---|---|---|
| anti-TNF | infliximab, adalimumab, golimumab (UC), certolizumab (CD) | IV / SC | ✓ | ✓ | severe or hospitalised disease, perianal fistula, spondyloarthritis, pregnancy | demyelination, NYHA III–IV heart failure, prior lymphoma, latent TB |
| anti-integrin | vedolizumab (Entyvio) | IV / SC | ✓ | ✓ | older or infection-prone, prior malignancy — gut-selective | slow onset; little effect on extraintestinal disease |
| IL-12/23 | ustekinumab (Stelara) | IV → SC | ✓ | ✓ | anti-TNF failure, psoriasis | — |
| IL-23 p19 | risankizumab (Skyrizi), mirikizumab (Omvoh), guselkumab (Tremfya) | IV → SC | ✓ | ✓ | anti-TNF-exposed CD (risankizumab over ustekinumab — conditional), psoriasis | — |
| JAK inhibitor | upadacitinib (Rinvoq), tofacitinib (Xeljanz, UC) | oral | ✓ (upa) | ✓ | rapid onset, oral, after anti-TNF failure | age ≥50 + CV risk, prior VTE, pregnancy |
| S1P modulator | ozanimod (Zeposia), etrasimod (Velsipity) | oral | — | ✓ | mild–moderate UC wanting oral therapy, proctitis (etrasimod) | conduction disease, recent MI/stroke, pregnancy |
Immunomodulators (not advanced therapy, but used alongside): azathioprine 1.5–2.5 mg/kg/day, 6-MP 0.75–1.5 mg/kg/day, methotrexate up to 25 mg SC/IM weekly (CD only). Too slow to induce; maintain after steroids and cut anti-drug antibodies when combined with infliximab (SONIC (2010)).
choosing
- Infliximab + thiopurine — the strongest single option in biologic-naive moderate–severe CD and in hospitalised UC. Infliximab is the usual inpatient anti-TNF in UC (ACG doesn’t rank it above adalimumab/golimumab).
- Vedolizumab over adalimumab in UC (VARSITY (2019): remission at week 52 31% vs 23%).
- Higher infection or malignancy risk (older, comorbid) → vedolizumab or IL-23 inhibitor (gut-selective or lower infection signal).
- First advanced therapy works best — response falls with each subsequent class.
- Primary non-response to a class → switch class. Secondary loss of response → trough level + antibodies: low level, no antibodies → dose-intensify; antibodies → switch within or across class.
- After 5-ASA failure, 5-ASA adds little to advanced therapy (conditional, very low evidence) — reasonable to stop.
- Biosimilars (infliximab, adalimumab, ustekinumab) are interchangeable for new starts and stable switches.
before the first dose
- HBV: HBsAg, anti-HBc, anti-HBs → HBsAg+ → antiviral prophylaxis; anti-HBc+ alone → monitor ALT and HBV DNA, or prophylaxis if anti-HBs low (viral hepatitis)
- TB: IGRA (or TST) + CXR → treat latent TB before anti-TNF
- HCV, HIV
- VZV serology if no history of chickenpox or vaccination
- Strongyloides serology if from an endemic area (before steroids)
- TPMT (± NUDT15) before azathioprine/6-MP
- Pregnancy test before JAKi, S1P modulator or methotrexate
- JAKi: lipids at baseline and 12 weeks
- S1P modulator: ECG (first-dose bradycardia, AV block); eye exam if diabetes or uveitis
vaccines (CAG 2021)
- Review vaccine history at diagnosis; vaccinate as early as possible, ideally before immunosuppression (inactivated ≥2 weeks, live ≥4 weeks before).
- Never delay urgently needed therapy to vaccinate.
- Live vaccines (MMR, varicella, yellow fever, BCG): not immunosuppressed and non-immune → MMR recommended (strong), varicella suggested in adults; on immunosuppression (biologics, JAKi, thiopurines, methotrexate, steroids) → suggest against (conditional); wait ≥3 months after stopping. Low-dose thiopurine/methotrexate/prednisone is a grey zone — degree of immunosuppression is the prescriber’s call.
- Recombinant zoster (Shingrix): recommended for IBD ≥50 years, suggested for adults <50.
- Inactivated influenza yearly (strong); HBV for non-immune adults (strong if risk factor, suggested otherwise); pneumococcal if on immunosuppression (suggested); HPV per NACI.
- Live vaccines in the first 6 months for infants exposed to biologics in utero: CAG made no recommendation (evidence insufficient) — decide with paediatrics.
- Full schedule → adult immunisation.
adverse effects
| class | what matters |
|---|---|
| anti-TNF | serious infection, TB reactivation; infusion reactions; drug-induced lupus; paradoxical psoriasis; demyelination; worsens heart failure |
| thiopurine (± anti-TNF) | myelosuppression (TPMT/NUDT15), pancreatitis, hepatotoxicity; lymphoma and non-melanoma skin cancer; hepatosplenic T-cell lymphoma in young men on combination therapy |
| vedolizumab | few — no PML signal (unlike natalizumab) |
| IL-12/23, IL-23 | few; infection rate close to placebo |
| JAKi | herpes zoster, VTE, raised lipids; MACE and cancer in older RA patients with CV risk (ORAL Surveillance) |
| S1P modulator | first-dose bradycardia and AV block, raised transaminases, macular oedema, infection |
Anti-TNF is safe in preconception, pregnancy and postpartum.
Ontario
- Ontario: ODB Limited Use covers infliximab, adalimumab and ustekinumab (CD and UC), tofacitinib and upadacitinib (UC). LU criteria require failed conventional therapy — stricter than ACG 2025, which doesn’t require it. Vedolizumab, IL-23 inhibitors and S1P modulators aren’t on the LU list → LU search.
Prepared 2026-10-28. Not yet verified — check every number against the sources.